AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
EDAP TMS Secures EUR 36M Credit Facility from European Investment Bank.
ByAinvest
Tuesday, Aug 26, 2025 7:03 am ET1min read
EDAP TMS SA has executed a letter of intent for a EUR 36 million credit facility with the European Investment Bank. Proceeds will support the growth of Focal One Robotic HIFU in Focal Therapy for early-stage prostate cancer, as well as accelerate the development of new clinical indications. The credit facility is expected to close by the end of 2025.
EDAP TMS SA (Nasdaq: EDAP), a leader in robotic energy-based therapies, has secured a letter of intent for a €36 million credit facility from the European Investment Bank (EIB). The financing will support the expansion of Focal One® Robotic HIFU technology for early-stage prostate cancer treatment and accelerate development of new clinical indications [1].The credit facility, expected to close by the end of 2025, will provide low-interest funding accessible in tranches. CEO Ryan Rhodes highlighted that this strategic financing will strengthen EDAP's balance sheet and help expand access to Focal One Robotic HIFU technology for physicians and patients [1].
EDAP TMS SA, recognized for its robotic energy-based therapies, develops, manufactures, promotes, and distributes worldwide minimally invasive medical devices using ultrasound technology. The company introduced the Focal One® in Europe and the U.S. as the leading prostate focal therapy controlled by urologists, with the potential to expand to multiple indications beyond prostate cancer [1].
The FLAME trial, evaluating the efficacy of focal radiation boost in prostate cancer treatment, found that dose escalation at the location of the primary tumor improved biochemical DFS without additional toxicity. Preliminary results indicated a 50% reduction in biochemical failures at 5 years [2].
This funding will bolster EDAP's efforts to enhance the accessibility and effectiveness of its Focal One Robotic HIFU technology, potentially benefiting millions of patients globally [1].
References:
[1] https://www.stocktitan.net/news/EDAP/edap-announces-letter-of-intent-for-36-million-euro-credit-facility-2ymdylq9plat.html
[2] https://www.medscape.com/viewarticle/focal-radiation-boost-enhances-prostate-cancer-control-2025a1000m71
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet